SACRAMENTO – (November 17, 2026) – Today, the American Lung Association in California released its annual “State of Lung Cancer” report, which shows the toll lung cancer takes on each state in the country. Lung cancer remains the leading cause of cancer deaths in California and the U.S. Nationally, more than 229,000 people will be diagnosed with the disease this year. For California, the report finds that the early diagnosis rate in California falls into the below average tier. The state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
California has improved access to screening by covering it through its fee-for-service Medicaid program. The Lung Association encourages all states to cover lung cancer screening based on recommended guidelines across all fee-for-service and managed care plans without any financial or administrative barriers in their Medicaid programs.
“Overall, our report reveals positive news—more people in the U.S. are living longer after a lung cancer diagnosis than ever before, and more people are getting screened for the disease.While these findings give us hope, more must be done to end the burden of this devastating disease on families throughout California,” said Kesa Bruce, director of advocacy for the American Lung Association. “It is alarming, however, that California falls into the below average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as cost and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.”
The “State of Lung Cancer” report examines key lung cancer indicators and ranks California:
- 3 out of 51 in the nation for rate of new lung cancer cases, at 36.3 per 100,000. The national rate is 52.1 per 100,000.
- 13 out of 43 in the nation for survival, at 33.2%. Most lung cancer cases are diagnosed at later stages when the cancer has spread, and treatment options are less likely to be curative. The national rate of people living five years after a lung cancer diagnosis is 31.0%.
- 39 out of 47 in the nation for early diagnosis, at 26.8%. The earlier lung cancer is diagnosed, the more likely that treatments will be effective. Nationally, only 29.3% of cases are diagnosed at an early stage.
- 12 out of 40 in the nation for surgical treatment, at 22.3%. Lung cancer can often be treated with surgery if it is diagnosed at an early stage and has not spread. Nationally, 21.4% of cases underwent surgery.
- 42 out of 47 in the nation for lack of treatment, at 25.3%. While there are multiple reasons why people may not receive treatment after a lung cancer diagnosis, no one should go untreated because of lack of provider or patient knowledge, lung cancer stigma, fatalism after diagnosis or cost of treatment. Nationally, 20.9% of cases receive no treatment.
- 48 out of 50 in the nation for lung cancer screening, at 15.8%. Lung cancer screening with annual low-dose CT scans for people at high risk can reduce the lung cancer death rate by up to 20%. Nationally, only 24.4% of people at high risk were screened.
- 5 out of 51 in the nation for radon, at 8.2%. Radon, a colorless and odorless gas that can be present at high levels inside homes and buildings, is the second leading cause of lung cancer. Every home should be regularly tested for radon and mitigated if results are high.
The “State of Lung Cancer” report also examines insurance coverage of comprehensive biomarker testing, which can help identify more personalized treatment options for a person’s specific type of lung cancer, including targeted therapies and immunotherapy. Insurance coverage of comprehensive biomarker testing is critical for making this test more accessible, but 24 states and Washington, D.C., do not require any coverage. The report found that California does require insurance coverage of comprehensive biomarker testing.
Additionally, clinical trials are essential to improving outcomes for people affected by lung cancer and increasing survival rates. Unfortunately, too many people face barriers that prevent them from participating in and benefitting from cutting edge research. The Lung Association is urging Congress to pass the Clinical Trial Modernization Act, which includes critical steps to make clinical trials accessible to more people and advance research and care for all.
The Lung Association brings research, advocacy and health promotions together to address lung cancer, investing in science, advocating for better access to prevention and care, and providing education, support and resources to help individuals navigate timely access to screening, diagnosis and treatment.
Learn more about the “State of Lung Cancer” report and take action to help end lung cancer at Lung.org/solc.
